➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Patent: 8,013,128

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,013,128
Title:Antibodies and related molecules that bind to PSCA proteins
Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
Inventor(s): Gudas; Jean (Los Angeles, CA), Jakobovits; Aya (Beverly Hills, CA), Jia; Xiao-chi (Los Angeles, CA), Morrison; Robert Kendall (Santa Monica, CA), Morrison; Karen Jane Meyrick (Santa Monica, CA), Shao; Hui (Los Angeles, CA), Challita-Eid; Pia M. (Encino, CA), Raitano; Arthur B. (Los Angeles, CA)
Assignee: Agensys, Inc. (Santa Monica, CA)
Application Number:12/397,992
Patent Claims:see list of patent claims

Details for Patent 8,013,128

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sigma Tau ONCASPAR pegaspargase VIAL 103411 001 1994-02-01   Start Trial Agensys, Inc. (Santa Monica, CA) 2039-02-26 RX search
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05   Start Trial Agensys, Inc. (Santa Monica, CA) 2039-02-26 RX search
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Agensys, Inc. (Santa Monica, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 8,013,128

Country Patent Number Estimated Expiration
South Africa 200509606   Start Trial
South Africa 200609894   Start Trial
World Intellectual Property Organization (WIPO) 2005014780   Start Trial
World Intellectual Property Organization (WIPO) 2005118864   Start Trial
World Intellectual Property Organization (WIPO) 2006112933   Start Trial
United States of America 2005221400   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.